Microbot Medical Inc. 8-K

What Happened

• On May 14, 2026, Microbot Medical Inc. announced (via press release furnished as Exhibit 99.1 to its Form 8‑K) that it recorded revenue from the limited market release of the LIBERTY® Endovascular Robotic System during Q1 2026.
• The company said its transition to a full market release has driven increased revenue in Q2 2026, and Q2 revenue has already exceeded Q1 as utilization and adoption accelerate across multiple sales territories.

Key Details

• Filing date: May 14, 2026 (Form 8‑K, Exhibit 99.1 press release).
• Revenue recognition: Recorded revenue from a limited market release in Q1 2026.
• Momentum: Transition to full market release led to higher Q2 2026 revenue that already surpasses Q1 levels.
• The disclosure includes standard forward‑looking statements regarding adoption and future results.

Why It Matters

• For investors, this filing provides the first public confirmation that Microbot is generating product revenue from commercial deployments of the LIBERTY system and that sales momentum increased after moving from limited to full market release.
• The company did not disclose dollar amounts or detailed quarterly financials in this filing, so investors should look for upcoming earnings reports or SEC filings for precise revenue figures and broader financial context.